Search PubMed⌕ Search

Biomedical subjects

T Kataoka

Publications and source records attributed to T Kataoka.

At least 307 records · Page 17Linked to original sources

Blastogenic potency of concanavalin-A-bound L1210 leukemic vaccine associated with its immunogenic activity.

Glutaraldehyde-treated L1210 murine leukemic cells induced immune resistance in mice when concanavalin-A (Con-A) was bound to their surface. They were not immunogenic when Con-A was separately inoculated, indicating requirement of vaccine-bound Con-A for enhancing immunogenic potency of the vaccine. Based on the finding that vaccine-bound Con-A induced in vitro blastogenesis of spleen cells 10 times as efficiently as unbound Con-A did, the association of blastogenic potency of Con-A-bound vaccine with its immunogenic activity was examined. The possibility of their association was supported by the finding that induction of immune resistance by vaccines was reduced when their blastogenic activities had been reduced by treatment of the vaccine with anti-Con-A antisera or by substituting succinyl-Con-A or other lectins for Con-A. Moreover, the fact that combined inoculations of Con-A-bound vaccine, assumed to be blastogenic to T cells, with anti-thymocyte sera, but not with cyclophosphamide or carrageenan, resulted in reduced production of resistant animals was also consistent with, but not proving, this possibility. Feasibility of this possibility was further supported by the finding that Con-A-bound vaccine did not induce immune resistance in animals that had been abrogated in blastogenic activity of spleen cells by prior administration of Con-A.

Animals↗

Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432.

Immunotherapeutic response to concanavalin A (Con A)-bound L1210 murine leukemic vaccine and immunopotentiators was examined in histocompatible animals bearing a small burden L1210 leukemic cells. When combined with Con A-bound vaccine, a streptococcal immunopotentiator, OK-432 (NSC B116209), prepared from Streptococcus pyogenes, was potent in antitumor therapy and resulted in a number of cured animals. Administration of either Con-A-bound vaccine or OK-432 alone did not produce any beneficial effect on leukemic animals. The enhanced therapeutic response was dependent on the effectiveness of the dose and timing of the administration of OK-432 when given after vaccination. Combined modality of Con A-bound L1210 vaccine and OK-432 was not effective in animals bearing P388 murine leukemic cells, which indicates specificity of therapeutic response. In enhancing the therapeutic potency of Con A-bound leukemia vaccine, pyran copolymer (NSC 46015) was as effective as OK-432, whereas Bacillus Calmette-Guérin and Corynebacterium parvum were far less effective. When combined with OK-432, therapeutic response to Con A-bound L1210 vaccine was much greater than response to glutaraldehyde-, mitomycin C-, or Vibrio cholerae neuraminidase-treated L1210 vaccine.

Animals↗

Potentiation of L1210 murine leukemia vaccine in vivo by levamisole.

Intraperitoneal inoculation of either levamisole or 2 x 10(6) cells of concanavalin-A (Con-A)-bound L1210 leukemia vaccine produced no cured mice after subsequent ip inoculation of 10(3) live L1210 cells. Combined inocluation of levamisole and Con-A-bound vaccine produced about 20% cure incidence but no prolongation of life span of tumor-bearing mice after inoculation of live L1210 cells. Combined inoculation of levamisole and Con A-free vaccine did not induce detectable immune resistance in mice. These results suggest that levamisole enhanced host response to cell-bound Con-A associated with immunogenic potency of the vaccine. Levamisole given intravenously and orally was as effective as that inoculated intraperitoneally in enhancing the induction of resistance in mice by Con-A-bound vaccine. Dose of levamisole was very critical for this enhancement, being effective at 0.38 mg/kg but not either at 0.75 or 0.19 mg/kg. Furthermore, levamisole restored immune resistance induced by a larger inoculum of Con-A-bound vaccine cells (10(7)) and impaired by cyclophosphamide.

Adjuvants, Immunologic↗

Organization of immunoglobulin heavy chain genes and allelic deletion model.

We have assessed the number of times the gene sequence encoding constant regions of mouse immunoglobulin heavy chains gamma1, gamma2a, and gamma3 are represented in the mouse genome by hybridization kinetic analysis. All three genes are present at one copy each per haploid genome in normal tissues and myelomas producing IgM or IgG3. IgG1-producing myelomas, however, contain 1 copy each of the gamma1 and gamma2a genes and 0.5 copy of the gamma3 gene per haploid genome. IgG2b-producing myelomas contain 1 copy of the gamma2a gene and 0.5 copy each of the gamma1 and gamma3 genes per haploid genome. IgG2a-producing myelomas contain 1 copy of the gamma2a gene and 0.5 copy each of the gamma1 and gamma3 genes per haploid genome. In myelomas producing IgA, all three gamma genes are represented 0.5 times per haploid genome. In order to account for the results we propose an allelic deletion model: (i) The specific deletion of heavy chain constant region genes accompanies the recombination of a variable region gene to a constant region gene. (ii) The portion of the chromosome that resides between two joining sequences is excised out of the chromosome. (iii) The recombination occurs on one of the alleles. Based on this model we also propose that heavy chain genes are arranged on one chromosome in the following order; variable region genes, unknown spacer sequence, mu, gamma3, gamma1, gamma2b, gamma2a, and alpha.

Alleles↗

Enhancement of chemotherapeutic effect by entrapping 1-beta-D-arabinofuranosylcytosine in lipid vesicles and its mode of action.

a-beta-D-arabinofuranosylcytosine (ara-C) trapped in multilamellar liposomes exerted enhanced chemotherapeutic effect against L1210 murine leukemia. Among four types of liposomes, the one composed of sphingomyelin, stearylamine and cholesterol was most potent in enhancing chemotherapeutic effect of ara-C. And the findings that ara-C was released gradually from liposome in vitro and that ara-C in liposome was chemotherapeutically effective against subsequently inoculated L1210 cells suggested that slow but long-lasting release of ara-C from liposome was partially responsible for enhanced chemotherapeutic effect.

Animals↗

Effect of combined use of anticancer drugs with a polysaccharide preparation, Krestin, on mouse leukemia P388.

When CDF1 mice inoculated intraperitoneally with leukemia P388 were treated intraperitoneally with mitomycin-C, of which dose was not so effective, on day 1 and given intraperitoneally polysaccharide preparation, Krestin, on day 2, 5, or 8 after tumor inoculation, best therapeutic results judged from 60-day survivors were obtained by combined use of mitomycin-C on day 1 and Krestin on day 5. Besides mitomycin-C, none of anticancer drugs such as cyclophosphamide, 5-fluorouracil, and 6-mercaptopurine was effective in this system. From these results, it was concluded that in this system, enhancement of anti-tumor effect of mitomycin-C by Krestin depends on the time of Krestin administration and that the combination effect is observed with mitomycin-C but not with cyclophosphamide, 5-fluorouracil, or 6-mercaptopurine.

Animals↗

Tumor-specific skin-reactive antigen solubilized from a syngeneic guinea pig liposarcoma by 3M potassium chloride.

Tumor-specific and skin-reactive antigen of a syngeneic liposarcoma (H-10) of Hartley/F guinea pig was solubilized with 3M potassium chloride and purified by precipitation with 2M ammonium sulfate, followed by Sephadex G-200 gel filtration. The antigenic activity of 7 fractions obtained was estimated by the delayed-type skin reaction elicited in syngeneic animals immunized with H-10 cells admixed with BCG. Accurate relative activity of the fractions comparable to the skin reaction elicited by living H-10 cells was calculated by the parallel line assay method in which the dose-response curves of the fractions are compared with that of living cells. About 30 approximately 50 microgram protein of the 3 fractions eluted slowly from the Sephadex column elicited the skin reaction equivalent to that elicited with 1 X 10(6) of living H-10 cells. Tumor-specific skin reactivity per microgram protein of these 3 fractions was roughly 20 approximately 40 times higher than that of lyophilized cells.

Animals↗

Enhancement of anti-tumor activity of 1-beta-D-arabinofuranosylcytosine by encapsulation in liposomes.

1-beta-D-Arabinofuranosylcytosine (ara-C) was encapsulated in four different types of unsonicated artificial vesicles of phospholipid (liposomes) to compare the anti-tumor effect on mouse leukemia L1210 inoculated in CD2F, mice with that of free ara-C. The anti-tumor activity of ara-C was markedly enhanced by encapsulation in liposomes when given in a single IP injection. Among the four types of liposomes, a physically stable and positively charged liposome consisting of sphingomyelin, stearylamine and cholesterol (20:2:15 molar ratio) most effectively enhanced the effect of ara-C. A single IP dose of 50 mg/kg of ara-C, encapsulated in this kind of liposome exhibited high activity, producing a survival rate of 60% of the treated mice at 60 days. This enhanced effect of ara-C encapsulated in liposomes was also demonstrated when the drug was administered either IV or SC, and the range between the minimum effective and the maximum tolerable doses was wide enough to allow the safe use of the encapsulated ara-C. Intraperitoneal administration of encapsulated ara-C induced a more prolonged survival of mice inocualted with L1210 than did free ara-C, regardless of whether it was given in single or multiple doses.

Administration, Oral↗

Responses of tumors induced in inbred guinea pig strain JY=1 and strain Hartley/F to BCG.

A transplantable fibrosarcoma induced in inbred JY-1 guinea pig strain by 3-methylcholanthrene (MCA) and designated J4, an allotransplantable subline of J4 (JH4) which was obtained by the transplantation of J4 into the inbred Hartley/F guinea pig strain and maintained by passages in this strain, and a syngeneic liposarcoma H10 induced in a Hartley/F guinea pig by MCA were tested for their immunotherapeutic response with BCG. The growth of J4 and H10 tumors was suppressed in most of the animals when tumor cells were mixed with BCG before being injected sc into BCG-immune or BCG-nonimmune recipients. The growth of the JH4 tumor was suppressed at the sites of injection with a mixture of tumor cells and BCG in BCG-immune recipients but not in nonimmune animals. All guinea pigs surviving the injection of a tumor cell-BCG mixture resisted a second tumor cell challenge. When subcutaneous sarcomas grew to about 8-15 mm in diameter, BCG was injected into the tumors. The growth of JH4 tumor was not influenced by the injection in either BCG-immune or BCG-nonimmune animals, while the regression of the established J4 transplants was produced in 2 of 3 nonimmune recipients. The growth of the H10 tumor was not inhibited with an intratumor injection into nonimmune guinea pigs, while the H10 tumor regressed in BCG-immune animals for 4-5 weeks after intratumor injection and thereafter grew progressively. Skin reactions in animals that received repeated intradermal injections of the tumor cells and BCG were tested with 10(6) viable tumor cells as eliciting antigens. Typical delayed-type hypersensitivity reactions that were specific to the homologous antigens were observed. The possible reasons for the different responses to BCG among the guinea pig tumors, including line-10 hepatocarcinoma in strain-2 guinea pigs, were discussed.

Animals↗

Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A.

Immunization with L1210 mouse leukemia cells treated with glutaraldehyde and concanavalin A resulted in the induction of leukemia-specific immune resistance in BALB/c X DBA/2Cr F1 mice. This was measured by survival of the mice after challenge either with the intact cells or with modified leukemia cells of less malignancy. Factors involved in the induction of immunoprophylaxis were analyzed. To produce an immune response against L1210 cells, preincubation with both glutaraldehyde and concanavalin A was required. Repeated sensitization with this combination produced higher incidences of survivors upon subsequent challenge with L1210 cells than did a single sensitization by equivalent or larger doses. However, the sensitization was rendered less effective by repetition of the immunization process five times.

Aldehydes↗

Enhanced induction of immune resistance by concanavalin A-bound L1210 vaccine and an immunopotentiator prepared from Coriolus versicolor.

Combined administration of a vaccine consisting of a small number (2 X 10(6)) of L1210 murine leukemic cells treated with glutaraldehyde and concanavalin A and a protein-bound polysaccharide preparation of Coriolus versicolor induced synergistic resistance to L1210 leukemia in BALB/c X DBA/2CrF1 mice. This effect was dependent on the dose and timing of the administration of the protein-bound polysaccharide preparation, being most effective at the time of or 1 day after the second vaccination. Induced resistance was not cross-reactive with P388 murine leukemia, indicating specificity of resistance. This immunopotentiation by the protein-bound polysaccharide did not occur when L1210 cells treated with glutaraldehyde, but not with concanavalin A, were used as a vaccine.

Animals↗

Some properties of bovine pineal tryptophan hydroxylase.

Bovine pineal tryptophan hydroxylase is a pterin-dependent aromatic amino acid monooxygenase with a broad substrate specificity and with low Km values for the amino acid substrates, L-tryptophan and L-phenylalanine. p-Chlorophenylalanine, an inhibitor of the tryptophan hydroxylation in the brain, also serves as a good substrate of the bovine pineal enzyme. The full activity of this enzyme is detected in vitro only after preincubation with dithiothreitol under reductive conditions. The enzyme is profoundly and more or less specifically inhibited by L-5HTP, the product of tryptophan hydroxylation, suggesting a possible regulatory role of this hydroxylated amino acid. The Km of the enzyme for tetrahydrobiopterin, a presumed natural cofactor, is significantly higher than the expected tissue concentration if the cofactor is assumed to be uniformly distributed in the tissue. These properties of bovine pineal tryptophan hydroxylase are distinguishable from those of the hydroxylase in the brain indicating that the hydroxylation of tryptophan in the brain leading to the synthesis of serotonin and the reaction in the pineal gland leading to the formation of melatonin are catalyzed by different tryptophan hydroxylases and are probably under separate regulatory mechanisms.

Animals↗